(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)

PETVIVO HIRES MR. RANDY WENTHOLD AS CSO

MINNEAPOLIS, Dec. 28, 2017 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCMARKETS:PETV) (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people has brought on Mr. Randy Wenthold into the position of Chief Science Officer. Mr. Wenthold will take over some of the responsibilities that Dr. Masters previously had on a day to day basis regarding product development, commercial production, and regulatory issues.

Dr. Masters has decided to resign from all his corporate positions with exception that he has chosen to remain as an active member of the Board of Directors of PetVivo Holdings, Inc.

“Now that the company is approaching commercial production, the addition of Mr. Wenthold into the position of Science Officer makes for a perfect fit. His experience in lab development and regulatory experience will allow us to address not only the initial production as scheduled, but also expand production capabilities given the success we expect with the launch of our first product,” stated PetVivo’s CEO, Wes Hayne.

Mr. Wenthold has been involved with medical devices from a development, manufacturing, and division management role for over 25 years. He was responsible for the development and market launch of the Renaflo acute renal failure family of filter products and Hemocor cardiosurgery fluid removal family of products (including the pediatric Junior device). Additional products he has developed are the Fibercor family of industrial filters, Vital Therapies ELAD and UFG filters, fiber used in an I-Flo drug delivery catheter, fiber or membranes used for implantable fiber devices and military water purification. Randy is named as the inventor of 3 patents and two provisional patents.

From 2012 until present he has been a medical device consultant specializing in the development of medical device products supporting cardiosurgery, sepsis and liver failure.

Mr. Wenthold stated, “I am excited to take on the role with Petvivo and build upon the previous contributions from Dr. Masters. I’m confident my previous experiences and expertise combined with those of the management team will contribute to the success planned for the company.”

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCMARKETS: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.    

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: (612) 296-7305
Direct: (763) 443-7272

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.